News

Wegovy maker Novo's profit warning triggers $70 billion share rout
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Why Novo Nordisk Stock Crumbled Again Today
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
WSKG3d
Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
Fierce Pharma4d
Novo Nordisk names new CEO as the obesity drugmaker cuts sales, profit outlook
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.
6abc News1y
Novo Nordisk to increase supply of Wegovy after demand-driven supply ...
Novo Nordisk has reaped huge profits from the sales of Wegovy and its sister diabetes medication Ozempic, reporting a total sales growth of 36% and an operating profit growth of 44% in 2023, but ...
Ozempic maker Novo Nordisk has its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...